¿Qué es el aclaramiento esofágico? ¿Cuáles son los factores agresivos? ¿Cuál es el rol de la Hernia del Hiato? ¿Qué factores de riesgo/protección se asocian. dr marugán tema reflujo gastroesofágico el reflujo es una cuestión de cantidad, todos tenemos reflujo pero cuando ese paso de contenido gástrico es mayor de . mediante pH-metría ambulatoria de 24 horas y un estudio isotópico con radionúclidos para determinar el aclaramiento esofágico de líquidos a largo plazo.
|Published (Last):||2 December 2012|
|PDF File Size:||1.4 Mb|
|ePub File Size:||16.66 Mb|
|Price:||Free* [*Free Regsitration Required]|
Clinical trials The European Union Clinical Trials Register allows you to search for protocol and results information on: Cancer AND drug name.
Pneumonia AND sponsor name. How to search [pdf].
Aclaramiento esofagico by diana minaya on Prezi
For these items you should use the filters and not add them to your search terms in the text field. Trials with results Trials without results Clear advanced search filters.
Review by the Competent Authority or Ethics Committee in the country concerned. EU Clinical Trials Register. Both Female Only Male Only.
IMP with orphan designation in the indication. Trials with results Trials without results.
Cirugía General MIP Flashcards
Clear advanced search filters. Date on which this record was first entered in the EudraCT database:. Title of the trial for lay aclaramento, in easily understood, i.
The IMP has been designated in this indication as an orphan drug in the Community. Committee on Advanced therapies CAT has issued a classification for this product. Combination product that includes a device, but does not involve an Advanced Therapy.
Esophageal, Gastroesophageal Junction and Gastric Cancer.
Testing may be performed by central laboratory prior to main study informed consent if subject signs a separate consent for the purposes of tumor tissue testing – Availability of recent preferred or archival tumor tissue – Measurable disease per RECIST 1.
Subject is a candidate for curative surgery or definitive chemoradiation. Currently receiving any anti-tumor treatments, or less than 14 days prior to enrollment since ending anti-tumor esofavico.
Johns Wort and other herbal supplements known to induce CYP3A4 less than 14 days prior to study day 1. Patient-reported outcomes assessment will be done at baseline and at every radiological assessment thereafter, including radiological assessments to confirm tumour progression when symptoms of disease progression occur.
FISIOLOGIA DIGESTIVA (BCM II) Clase 3: Fisiopatología Esofágica Dr. Michel Baró Aliste.
CTC and circulating serum biomarkers will also be assessed at baseline and during study treatment. Health-related quality of life. The trial involves single site in the Member State concerned.
Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial. Plans for treatment or care after the subject has ended the participation in the trial if it esofagoco different from the expected normal treatment of that condition.